Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) pipeline Target constitutes close to 45 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8, 5, 1, 20 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease and Women's Health which include indications Multiple Sclerosis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Non-Alcoholic Steatohepatitis (NASH), Chronic Kidney Disease (Chronic Renal Failure), Huntington Disease, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Systemic Sclerosis (Scleroderma), Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Asthma, Focal Segmental Glomerulosclerosis (FSGS), Friedreich Ataxia, Inflammation, Inflammatory Bowel Disease, Mitochondrial Myopathy, Neurodegenerative Diseases, Osteoarthritis, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Arterial Hypertension, Retinal Degeneration, Sickle Cell Disease, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes, Acne Vulgaris, Acute Renal Failure (ARF) (Acute Kidney Injury), Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), Age Related Macular Degeneration, Alport Syndrome, Asbestosis, Aspiration Pneumonitis, Atherosclerosis, Beta Thalassaemia, Breast Cancer, Bullous Pemphigoid, Cardiomyopathy, Cerebral Vasospasm, Coronavirus Disease 2019 (COVID-19), Dementia, Diabetic Complications, Diffuse Large B-Cell Lymphoma, Duchenne Muscular Dystrophy, Encephalomyelitis, Epidermolysis Bullosa, Epilepsy, Fibrosis, Glioblastoma Multiforme (GBM), Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Idiopathic Pulmonary Fibrosis, IgA Nephropathy (Berger's Disease), Ischemia Reperfusion Injury, Ischemic Stroke, Juvenile Myelomonocytic Leukemia (JMML), Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy), Kidney Disease (Nephropathy), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Lung Injury, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoporosis, Ovarian Cancer, Pervasive Developmental Disorder (PDD), Polycystic Kidney Disease, Polycystic Ovarian Syndrome, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Pulmonary Fibrosis, Pulmonary Hypertension, Refractory Medulloblastoma, Retinopathy, Secondary Progressive Multiple Sclerosis (SPMS), Spinocerebellar Ataxia (SCA), Subacute Necrotizing Encephalomyelopathy (Leigh Disease) and Ulcerative Colitis.
The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Drugs In Development, 2022, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) pipeline Target constitutes close to 45 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8, 5, 1, 20 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease and Women's Health which include indications Multiple Sclerosis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Non-Alcoholic Steatohepatitis (NASH), Chronic Kidney Disease (Chronic Renal Failure), Huntington Disease, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Systemic Sclerosis (Scleroderma), Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Asthma, Focal Segmental Glomerulosclerosis (FSGS), Friedreich Ataxia, Inflammation, Inflammatory Bowel Disease, Mitochondrial Myopathy, Neurodegenerative Diseases, Osteoarthritis, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Arterial Hypertension, Retinal Degeneration, Sickle Cell Disease, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes, Acne Vulgaris, Acute Renal Failure (ARF) (Acute Kidney Injury), Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), Age Related Macular Degeneration, Alport Syndrome, Asbestosis, Aspiration Pneumonitis, Atherosclerosis, Beta Thalassaemia, Breast Cancer, Bullous Pemphigoid, Cardiomyopathy, Cerebral Vasospasm, Coronavirus Disease 2019 (COVID-19), Dementia, Diabetic Complications, Diffuse Large B-Cell Lymphoma, Duchenne Muscular Dystrophy, Encephalomyelitis, Epidermolysis Bullosa, Epilepsy, Fibrosis, Glioblastoma Multiforme (GBM), Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Idiopathic Pulmonary Fibrosis, IgA Nephropathy (Berger's Disease), Ischemia Reperfusion Injury, Ischemic Stroke, Juvenile Myelomonocytic Leukemia (JMML), Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy), Kidney Disease (Nephropathy), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Lung Injury, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoporosis, Ovarian Cancer, Pervasive Developmental Disorder (PDD), Polycystic Kidney Disease, Polycystic Ovarian Syndrome, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Pulmonary Fibrosis, Pulmonary Hypertension, Refractory Medulloblastoma, Retinopathy, Secondary Progressive Multiple Sclerosis (SPMS), Spinocerebellar Ataxia (SCA), Subacute Necrotizing Encephalomyelopathy (Leigh Disease) and Ulcerative Colitis.
The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Drugs In Development, 2022, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Overview
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Companies Involved in Therapeutics Development
AKL Research and Development Ltd
Annji Pharmaceutical Co Ltd
Anteris Bio
Arbor Pharmaceuticals LLC
Bach Pharma Inc
Bayer AG
BioApex sro
Biogen Inc
Biotoxtech Co Ltd
C4X Discovery Holdings Plc
Cellix Bio Pvt Ltd
Complexa Inc
Cureveda LLC
Daiichi Sankyo Co Ltd
Erganeo
Evgen Pharma Plc
Haisco Pharmaceutical Group Co Ltd
Immungenetics AG
Ixchel Pharma LLC
Lignamed LLC
Mariposa Therapeutics Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rescue Therapeutics Inc
Scohia Pharma Inc
Sulfateq BV
Vitalis LLC
Vividion Therapeutics Inc
vTv Therapeutics Inc
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Drug Profiles
(apocynin + paeonol) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(aspirin + dimethyl fumarate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(aspirin + diroximel fumarate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(aspirin + monomethyl fumarate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALZ-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALZ-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BA-1521 - Drug Profile
Product Description
Mechanism Of Action
bardoxolone methyl - Drug Profile
Product Description
Mechanism Of Action
History of Events
BTT-105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
C4X-6746 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CLXNEU-06 - Drug Profile
Product Description
Mechanism Of Action
CXA-10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DH-404 - Drug Profile
Product Description
Mechanism Of Action
dimethyl fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
dimethyl fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
dimethyl fumarate DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
diroximel fumarate DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
HPP-3033 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HPP-971 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HSK-36212 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HYCO-13 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IXC-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LGM-2605 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MG-132 - Drug Profile
Product Description
Mechanism Of Action
MIND-4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
monosodium luminol - Drug Profile
Product Description
Mechanism Of Action
History of Events
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
History of Events
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
RS-9 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RTI-79 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SCO-116 - Drug Profile
Product Description
Mechanism Of Action
SFX-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SFX-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate NFE2L2 for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Activate NFE2L2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Activate NRF2 for Chronic Kidney Disease and Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Nrf2 for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
SUL-121 - Drug Profile
Product Description
Mechanism Of Action
TBE-31 - Drug Profile
Product Description
Mechanism Of Action
tepilamide fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
TFM-735 - Drug Profile
Product Description
Mechanism Of Action
VCB-102 - Drug Profile
Product Description
Mechanism Of Action
VEDA-1209 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Dormant Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Discontinued Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Product Development Milestones
Featured News & Press Releases
Apr 04, 2022: Biogen announces new update on VUMERITY at AAN 2022
Mar 31, 2022: Reata Pharmaceuticals completes rolling submission of new drug application for Omaveloxolone for the treatment of patients with Friedreich’s Ataxia
Mar 17, 2022: Viatris defeats Biogen's attempt to Revive Tecfidera patent
Mar 07, 2022: Evgen Pharma : Expansion of collaboration with the Manchester Breast Centre
Feb 25, 2022: Reata Pharmaceuticals receives complete response letter from the FDA for bardoxolone for the treatment of patients with chronic kidney disease caused by Alport syndrome
Feb 15, 2022: Haisco's announcement on obtaining the "Notice of Acceptance" for clinical trial application of innovative drug HSK36212 capsules
Jan 31, 2022: Reata Pharmaceuticals initiates rolling submission of new drug application with U.S. FDA for Omaveloxolone for the treatment of patients with Friedreich’s ataxia
Jan 11, 2022: Evgen Pharma: Progress with UK and US regulators for 2022 clinical trials
Dec 14, 2021: Imara presents preclinical data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
Dec 08, 2021: Reata Pharmaceuticals announces outcome of FDA advisory committee meeting of Bardoxolone for the treatment of patients with chronic kidney disease caused by alport syndrome
Dec 08, 2021: Reata Pharmaceuticals stock trading halted; FDA Advisory Committee to discuss bardoxolone for the treatment of patients with chronic kidney disease caused by Alport Syndrome
Dec 01, 2021: Viatris wins Federal circuit court appeal upholding district court decision invalidating Biogen's Tecfidera Patent
Nov 18, 2021: Reata Pharmaceuticals receives Fast Track Designation from the FDA for Omaveloxolone for the treatment of Friedreich’s Ataxia
Nov 16, 2021: The European Commission grants marketing authorization for VUMERITY (diroximel fumarate) as oral treatment for relapsing-remitting multiple sclerosis
Nov 10, 2021: Evgen Pharma: Publication of data on SFX-01 in glioblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Overview
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Companies Involved in Therapeutics Development
AKL Research and Development Ltd
Annji Pharmaceutical Co Ltd
Anteris Bio
Arbor Pharmaceuticals LLC
Bach Pharma Inc
Bayer AG
BioApex sro
Biogen Inc
Biotoxtech Co Ltd
C4X Discovery Holdings Plc
Cellix Bio Pvt Ltd
Complexa Inc
Cureveda LLC
Daiichi Sankyo Co Ltd
Erganeo
Evgen Pharma Plc
Haisco Pharmaceutical Group Co Ltd
Immungenetics AG
Ixchel Pharma LLC
Lignamed LLC
Mariposa Therapeutics Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rescue Therapeutics Inc
Scohia Pharma Inc
Sulfateq BV
Vitalis LLC
Vividion Therapeutics Inc
vTv Therapeutics Inc
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Drug Profiles
(apocynin + paeonol) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(aspirin + dimethyl fumarate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(aspirin + diroximel fumarate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(aspirin + monomethyl fumarate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALZ-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALZ-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BA-1521 - Drug Profile
Product Description
Mechanism Of Action
bardoxolone methyl - Drug Profile
Product Description
Mechanism Of Action
History of Events
BTT-105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
C4X-6746 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CLXNEU-06 - Drug Profile
Product Description
Mechanism Of Action
CXA-10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DH-404 - Drug Profile
Product Description
Mechanism Of Action
dimethyl fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
dimethyl fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
dimethyl fumarate DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
diroximel fumarate DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
HPP-3033 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HPP-971 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HSK-36212 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HYCO-13 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IXC-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LGM-2605 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MG-132 - Drug Profile
Product Description
Mechanism Of Action
MIND-4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
monosodium luminol - Drug Profile
Product Description
Mechanism Of Action
History of Events
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
History of Events
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
RS-9 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RTI-79 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SCO-116 - Drug Profile
Product Description
Mechanism Of Action
SFX-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SFX-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate NFE2L2 for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Activate NFE2L2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Activate NRF2 for Chronic Kidney Disease and Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Nrf2 for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
SUL-121 - Drug Profile
Product Description
Mechanism Of Action
TBE-31 - Drug Profile
Product Description
Mechanism Of Action
tepilamide fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
TFM-735 - Drug Profile
Product Description
Mechanism Of Action
VCB-102 - Drug Profile
Product Description
Mechanism Of Action
VEDA-1209 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Dormant Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Discontinued Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Product Development Milestones
Featured News & Press Releases
Apr 04, 2022: Biogen announces new update on VUMERITY at AAN 2022
Mar 31, 2022: Reata Pharmaceuticals completes rolling submission of new drug application for Omaveloxolone for the treatment of patients with Friedreich’s Ataxia
Mar 17, 2022: Viatris defeats Biogen's attempt to Revive Tecfidera patent
Mar 07, 2022: Evgen Pharma : Expansion of collaboration with the Manchester Breast Centre
Feb 25, 2022: Reata Pharmaceuticals receives complete response letter from the FDA for bardoxolone for the treatment of patients with chronic kidney disease caused by Alport syndrome
Feb 15, 2022: Haisco's announcement on obtaining the "Notice of Acceptance" for clinical trial application of innovative drug HSK36212 capsules
Jan 31, 2022: Reata Pharmaceuticals initiates rolling submission of new drug application with U.S. FDA for Omaveloxolone for the treatment of patients with Friedreich’s ataxia
Jan 11, 2022: Evgen Pharma: Progress with UK and US regulators for 2022 clinical trials
Dec 14, 2021: Imara presents preclinical data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
Dec 08, 2021: Reata Pharmaceuticals announces outcome of FDA advisory committee meeting of Bardoxolone for the treatment of patients with chronic kidney disease caused by alport syndrome
Dec 08, 2021: Reata Pharmaceuticals stock trading halted; FDA Advisory Committee to discuss bardoxolone for the treatment of patients with chronic kidney disease caused by Alport Syndrome
Dec 01, 2021: Viatris wins Federal circuit court appeal upholding district court decision invalidating Biogen's Tecfidera Patent
Nov 18, 2021: Reata Pharmaceuticals receives Fast Track Designation from the FDA for Omaveloxolone for the treatment of Friedreich’s Ataxia
Nov 16, 2021: The European Commission grants marketing authorization for VUMERITY (diroximel fumarate) as oral treatment for relapsing-remitting multiple sclerosis
Nov 10, 2021: Evgen Pharma: Publication of data on SFX-01 in glioblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AKL Research and Development Ltd, 2022
Pipeline by Annji Pharmaceutical Co Ltd, 2022
Pipeline by Anteris Bio, 2022
Pipeline by Arbor Pharmaceuticals LLC, 2022
Pipeline by Bach Pharma Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by BioApex sro, 2022
Pipeline by Biogen Inc, 2022
Pipeline by Biotoxtech Co Ltd, 2022
Pipeline by C4X Discovery Holdings Plc, 2022
Pipeline by Cellix Bio Pvt Ltd, 2022
Pipeline by Complexa Inc, 2022
Pipeline by Cureveda LLC, 2022
Pipeline by Daiichi Sankyo Co Ltd, 2022
Pipeline by Erganeo, 2022
Pipeline by Evgen Pharma Plc, 2022
Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
Pipeline by Immungenetics AG, 2022
Pipeline by Ixchel Pharma LLC, 2022
Pipeline by Lignamed LLC, 2022
Pipeline by Mariposa Therapeutics Ltd, 2022
Pipeline by Mochida Pharmaceutical Co Ltd, 2022
Pipeline by Reata Pharmaceuticals Inc, 2022
Pipeline by Rescue Therapeutics Inc, 2022
Pipeline by Scohia Pharma Inc, 2022
Pipeline by Sulfateq BV, 2022
Pipeline by Vitalis LLC, 2022
Pipeline by Vividion Therapeutics Inc, 2022
Pipeline by vTv Therapeutics Inc, 2022
Dormant Products, 2022
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AKL Research and Development Ltd, 2022
Pipeline by Annji Pharmaceutical Co Ltd, 2022
Pipeline by Anteris Bio, 2022
Pipeline by Arbor Pharmaceuticals LLC, 2022
Pipeline by Bach Pharma Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by BioApex sro, 2022
Pipeline by Biogen Inc, 2022
Pipeline by Biotoxtech Co Ltd, 2022
Pipeline by C4X Discovery Holdings Plc, 2022
Pipeline by Cellix Bio Pvt Ltd, 2022
Pipeline by Complexa Inc, 2022
Pipeline by Cureveda LLC, 2022
Pipeline by Daiichi Sankyo Co Ltd, 2022
Pipeline by Erganeo, 2022
Pipeline by Evgen Pharma Plc, 2022
Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
Pipeline by Immungenetics AG, 2022
Pipeline by Ixchel Pharma LLC, 2022
Pipeline by Lignamed LLC, 2022
Pipeline by Mariposa Therapeutics Ltd, 2022
Pipeline by Mochida Pharmaceutical Co Ltd, 2022
Pipeline by Reata Pharmaceuticals Inc, 2022
Pipeline by Rescue Therapeutics Inc, 2022
Pipeline by Scohia Pharma Inc, 2022
Pipeline by Sulfateq BV, 2022
Pipeline by Vitalis LLC, 2022
Pipeline by Vividion Therapeutics Inc, 2022
Pipeline by vTv Therapeutics Inc, 2022
Dormant Products, 2022
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
